Specialty Pharmacy

Compounded drugs accounted for more than half of cost increases under Medicare Part D in the last year.

Descovy showed non-inferiority to Truvada, and benefited bone and kidney health.

Keytruda approved as a first-line treatment for non-small cell lung cancer.

Swedish study suggests that more American men can opt surveillance over prostate cancer treatment.

Paul LeVine, vice president of Analytic Services at TrialCard, discusses how specialty pharmacies can best support patients on a specialty drug therapy.

Although any amount of exercise is beneficial, exceeding the recommended level produces the most benefits for diabetes patients.

Top news of the day from across the health care landscape.

Xgeva targets the RANK ligand pathways to prevent the creation, function, and survival of osteoclasts.

Novel PCSK9 inhibitor bococizumab halted after manufacturer determines limited value.

New findings reveal 2 subsets of the disease which may have an effect on how the disease responds to standard therapy.

Ibalizumab caused 83% of HIV-positive patients to achieve a virologic response.

A specific mark in histones speeds up repairs in cancer cells, increasing their resistance to treatment.

Top news of the day from across the health care landscape.

A novel approach looks to provide researchers with the tools to make accurate and safe predictions for cancer patients.

Premiums in employer plans are growing more slowly on average, as are individual income levels.

An automated algorithm was able to select HIV-positive individuals who would benefit the most from PrEP.

Ribociclib treats patients with HR+/HER2- advanced or metastatic breast cancer.

As symptoms of depression worsen, so too does the length of survival in lung cancer patients, according to a study published in the Journal of Clinical Oncology.

Unexpected benefits seen in patients with hemophilia A when a common protein was blocked.

Fission yeast is a low cost and fast system that can improve the cancer drug discovery process.

Top news of the day from across the health care landscape.

Ustekinumab is a monoclonal antibody approved by the FDA to treat plaque psoriasis, psoriatic arthritis, and active Crohn's disease.

Rosuvastatin is the generic version of Crestor tablets from AstraZeneca.

Dolutegravir/abacavir shows a solid safety profile and a high barrier to resistance.

Specialty pharmacy relies heavily on the constantly-evolving development of new medicines and therapies.

The FDA discovered deficiencies in a Sanofi manufacturing facility for the rheumatoid arthritis drug sarilumab.

Top news of the day from across the health care landscape.